Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 15/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.52 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29813497 | 1.00 | LPAR1 (0.52) | LPAR1CYP3A4AKR1C1LMNAKMT2A | |
| Hydrochloric Acid SCHEMBL21582553 | 0.98 | LPAR1 (0.51) | LPAR1CYP3A4AKR1C1LMNAKMT2A | |
| Hydrochloric Acid SCHEMBL29813329 | 0.98 | LPAR1 (0.51) | LPAR1CYP3A4AKR1C1LMNAKMT2A | |
| SCHEMBL23721588 | 0.86 | LPAR1 (0.51) | LPAR1CYP3A4GABRA1GABRB2 | |
| SCHEMBL30844690 | 0.86 | LPAR1 (0.51) | LPAR1CYP3A4GABRA1GABRB2 | |
| SCHEMBL21582362 | 0.84 | LPAR1 (0.54) | LPAR1CYP3A4AKR1C1 | |
| SCHEMBL30844788 | 0.84 | LPAR1 (0.54) | LPAR1CYP3A4AKR1C1 | |
| Hydrochloric Acid SCHEMBL30844853 | 0.84 | LPAR1 (0.50) | LPAR1CYP3A4GABRA1GABRB2 | |
| SCHEMBL25001523 | 0.82 | LPAR1 (0.41) | LPAR1CYP3A4AKR1C1LMNAKMT2A | |
| SCHEMBL30168354 | 0.82 | LPAR1 (0.41) | LPAR1CYP3A4AKR1C1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12539294-B2 | Combination of an azetidine LPA1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases | IDORSIA PHARMACEUTICALS LTD (CH) | 2026-02-03 | — | — | US | disclosed |
| US-12479820-B2 | Pyridin-3-yl derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-11-25 | — | — | US | disclosed |
| US-12344597-B2 | Alkoxy-substituted pyridinyl derivatives as LPA1 receptor antagonists and their use in the treatment of fibrosis | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-07-01 | — | — | US | disclosed |
| CN-114026082-B | Pyridin-3-yl derivatives | 爱杜西亚药品有限公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-112236424-B | Alkoxy-substituted pyridinyl derivatives | 爱杜西亚药品有限公司 | 2024-03-15 | — | — | CN | disclosed |
| US-20230000846-A1 | COMBINATION OF AN AZETIDINE LPA1 RECEPTOR ANTAGONIST WITH PIRFENIDONE AND/OR NINTEDANIB FOR USE IN THE TREATMENT OF FIBROTIC DISEASES | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-01-05 | — | — | US | disclosed |
| EP-3802517-B1 | ALKOXY-SUBSTITUTED PYRIDINYL DERIVATIVES AS LPA1 RECEPTOR ANTAGONISTS AND THEIR USE IN THE TREATMENT OF FIBROSIS | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-12-21 | — | — | EP | disclosed |
| EP-4069227-A1 | COMBINATION OF AN AZETIDINE LPA1 RECEPTOR ANTAGONIST WITH PIRFENIDONE AND/OR NINTEDANIB FOR USE IN THE TREATMENT OF FIBROTIC DISEASES | Idorsia Pharmaceuticals Ltd (CH) | 2022-10-12 | — | — | EP | disclosed |
| US-20220251068-A1 | PYRIDIN-3-YL DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-08-11 | — | — | US | disclosed |
| CN-114761001-A | Combination of azetidine LPA1 receptor antagonists with anti-fibrotic agents | 爱杜西亚药品有限公司 | 2022-07-15 | — | — | CN | disclosed |
| EP-3986884-A1 | PYRIDIN-3-YL DERIVATIVES | Idorsia Pharmaceuticals Ltd (CH) | 2022-04-27 | — | — | EP | disclosed |
| CN-114026082-A | Pyridin-3-yl derivatives | 爱杜西亚药品有限公司 | 2022-02-08 | — | — | CN | disclosed |
| US-20210246116-A1 | ALKOXY-SUBSTITUTED PYRIDINYL DERIVATIVES AS LPA1 RECEPTOR ANTAGONISTS AND THEIR USE IN THE TREATMENT OF FIBROSIS | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-08-12 | — | — | US | disclosed |
| WO-2021110805-A1 | COMBINATION OF AN AZETIDINE LPA1 RECEPTOR ANTAGONIST WITH PIRFENIDONE AND/OR NINTEDANIB FOR USE IN THE TREATMENT OF FIBROTIC DISEASES | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-06-10 | — | — | WO | disclosed |
| EP-3802517-A1 | ALKOXY-SUBSTITUTED PYRIDINYL DERIVATIVES AS LPA1 RECEPTOR ANTAGONISTS AND THEIR USE IN THE TREATMENT OF FIBROSIS | Idorsia Pharmaceuticals Ltd (CH) | 2021-04-14 | — | — | EP | disclosed |
| CN-112236424-A | Alkoxy-substituted pyridyl derivatives | 爱杜西亚药品有限公司 | 2021-01-15 | — | — | CN | disclosed |
| WO-2020254408-A1 | PYRIDIN-3-YL DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2020-12-24 | — | — | WO | disclosed |
| WO-2019234115-A1 | ALKOXY-SUBSTITUTED PYRIDINYL DERIVATIVES AS LPA1 RECEPTOR ANTAGONISTS AND THEIR USE IN THE TREATMENT OF FIBROSIS | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12344597-B2 | Alkoxy-substituted pyridinyl derivatives as LPA1 receptor antagonists and their use in the treatment of fibrosis | LPAR1, LPAR3, LPAR2 | LPAR1 1/4885CYP3A4 2430/4885AKR1C1 329/4885 |
| US-12539294-B2 | Combination of an azetidine LPA1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases | LPAR2, LPAR1, LPAR3 | LPAR1 2/4885CYP3A4 4443/4885AKR1C1 1862/4885 |
| US-20230000846-A1 | COMBINATION OF AN AZETIDINE LPA1 RECEPTOR ANTAGONIST WITH PIRFENIDONE AND/OR NINTEDANIB FOR USE IN THE TREATMENT OF FIBROTIC DISEASES | LPAR1, LPAR2, LPAR3 | LPAR1 1/4885CYP3A4 4452/4885AKR1C1 656/4885 |
| US-20220251068-A1 | PYRIDIN-3-YL DERIVATIVES | LPAR1, LPAR3, LPAR2 | LPAR1 1/4885CYP3A4 1290/4885AKR1C1 395/4885 |
| US-20210246116-A1 | ALKOXY-SUBSTITUTED PYRIDINYL DERIVATIVES AS LPA1 RECEPTOR ANTAGONISTS AND THEIR USE IN THE TREATMENT OF FIBROSIS | LPAR1, LPAR3, LPAR2 | LPAR1 1/4885CYP3A4 2430/4885AKR1C1 329/4885 |
| US-12479820-B2 | Pyridin-3-yl derivatives | LPAR1, LPAR3, LPAR2 | LPAR1 1/4885CYP3A4 1290/4885AKR1C1 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.